You are here: Industry Insights > CAR T

News List

BMS’ CAR T therapy Abecma moves closer toward EU approval pharmatimes
June 29, 2021
Bristol Myers Squibb’s (BMS) CAR T cell therapy Abecma has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of relapsed and ...
CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial europeanpharmaceuticalreview
June 18, 2021
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma expresspharma
March 29, 2021
Abecma is a first-in-class BCMA-directed personalised immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma.
CAR T therapy provides long-lasting remissions in non-hodgkin lymphoma europeanpharmaceuticalreview
February 20, 2021
Study shows most non-Hodgkin’s lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
Immuneel, HCB and IDIBAPS enter into a collaboration and licensing agreement for CAR T cell therapy expresspharma
October 15, 2020
Immuneel acquires exclusive license to CD19 CAR T product for the potential treatment of B cell malignancies for India.
US researchers develop CAR T cell therapy for cancer pharmaceutical-technology
September 27, 2019
Researchers at the City of Hope cancer research centre are developing a chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed blood cancers.
CAR T for Large Tumors: The Next Frontier? contractpharma
September 12, 2019
Traditional cancer treatments tend to be unprecise, the effect of which both healthy and cancerous cells are destroyed. Chemotherapy or radiation are like the military carpet bombing an area...
Immune cells fighting blood cancer visualized for the first time worldpharmanews
April 10, 2019
When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease...
Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL) pharmafocusasia
December 03, 2018
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer......
NHS England appoves Gilead's CAR T therapy Yescarta pharmafile
November 20, 2018
Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive non-Hodgkin lymphoma, it was announced today.

Previous page 1 2 Next page